SR One, the corporate venture capital arm of GlaxoSmithKline, has led a $30m funding round for London-based biotechnology company Pulmocide.
Catch up on essential news and features from this past week with our round-up of industry analysis
With the fresh capital, IM Square plans to acquire three to six additional asset managers
Historical investors, including the Region Paris Venture fund and Sibessor2/Investessor, also take part
Early-stage investors High-Tech Gründerfonds and Bayern Kapital are also taking part